These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 6681401)

  • 1. Statistical issues in the design and analysis of carcinogenicity bioassays.
    Hajian G
    Toxicol Pathol; 1983; 11(1):83-9. PubMed ID: 6681401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Statistical support of the proposed National Toxicology Program protocol.
    Haseman JK
    Toxicol Pathol; 1983; 11(1):77-82. PubMed ID: 6681400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statistical issues in the design, analysis and interpretation of animal carcinogenicity studies.
    Haseman JK
    Environ Health Perspect; 1984 Dec; 58():385-92. PubMed ID: 6525993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are tumor incidence rates from chronic bioassays telling us what we need to know about carcinogens?
    Gaylor DW
    Regul Toxicol Pharmacol; 2005 Mar; 41(2):128-33. PubMed ID: 15698536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of historical controls for animal experiments.
    Yanagawa T; Hoel DG
    Environ Health Perspect; 1985 Nov; 63():217-24. PubMed ID: 4076086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exact significance levels for multiple binomial testing with application to carcinogenicity screens.
    Brown CC; Fears TR
    Biometrics; 1981 Dec; 37(4):763-74. PubMed ID: 7337794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Statistical issues in interpretation of chronic bioassay tests for carcinogenicity.
    Gart JJ; Chu KC; Tarone RE
    J Natl Cancer Inst; 1979 Apr; 62(4):957-74. PubMed ID: 285297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Trp53 hemizygous mouse in pharmaceutical development: points to consider for pathologists.
    Floyd E; Mann P; Long G; Ochoa R
    Toxicol Pathol; 2002; 30(1):147-56. PubMed ID: 11890468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A guide to the statistical analysis of long-term carcinogenicity assays.
    McKnight B
    Fundam Appl Toxicol; 1988 Feb; 10(2):355-64. PubMed ID: 3356323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discussion on statistical analysis of carcinogenicity studies with an early terminated treated group.
    Saul J; Ashcroft-Hawley K
    Pharm Stat; 2020 May; 19(3):326-334. PubMed ID: 31830352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Tg rasH2 mouse in cancer hazard identification.
    Morton D; Alden CL; Roth AJ; Usui T
    Toxicol Pathol; 2002; 30(1):139-46. PubMed ID: 11890467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Initiation/promotion designs in carcinogenicity bioassays.
    Hayashi Y
    Toxicol Pathol; 1983; 11(2):143-8. PubMed ID: 6681408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NTP toxicology and carcinogenesis studies of 3,3',4,4',5-pentachlorobiphenyl (PCB 126) (CAS No. 57465-28-8) in female Harlan Sprague-Dawley rats (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 2006 Jan; (520):4-246. PubMed ID: 16628245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review and evaluation of the NCI/NTP carcinogenesis bioassays.
    Hottendorf GH; Pachter IJ
    Toxicol Pathol; 1985; 13(2):141-6. PubMed ID: 3901224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Value of historical control data and other issues related to the evaluation of long-term rodent carcinogenicity studies.
    Haseman JK; Boorman GA; Huff J
    Toxicol Pathol; 1997; 25(5):524-7. PubMed ID: 9323846
    [No Abstract]   [Full Text] [Related]  

  • 16. Mouse-specific carcinogens: an assessment of hazard and significance for validation of short-term carcinogenicity bioassays in transgenic mice.
    Battershill JM; Fielder RJ
    Hum Exp Toxicol; 1998 Apr; 17(4):193-205. PubMed ID: 9617631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 2nd International symposium of the Society of Toxicologic Pathologists. Design of carcinogenicity studies: considerations in pathology interpretation. May 9-11, 1983, Arlington, Virginia.
    Toxicol Pathol; 1983; 11(2):132-207. PubMed ID: 6681406
    [No Abstract]   [Full Text] [Related]  

  • 18. 2nd International symposium of the Society of Toxicologic Pathologists. Design of carcinogenicity studies: considerations in pathology interpretation. May 9-11, 1983, Arlington, Virginia.
    Toxicol Pathol; 1983; 11(1):28-95. PubMed ID: 6681393
    [No Abstract]   [Full Text] [Related]  

  • 19. Improving the power of long term rodent carcinogenicity bioassays by adjusting the experimental design.
    Jackson MT
    Regul Toxicol Pharmacol; 2015 Jul; 72(2):231-43. PubMed ID: 25908510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of statistics when examining lifetime studies in rodents to detect carcinogenicity.
    Salsburg DS
    J Toxicol Environ Health; 1977 Nov; 3(4):611-28. PubMed ID: 592429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.